Peter (Pete) Garcia serves as Chief Financial Officer at CatalYm. He brings more than three decades of biotechnology and oncology financial leadership experience, with a proven track record of leading transformative financings, strategic transactions, and scaling finance organizations to support global clinical development and commercialization. Throughout his career, Pete has raised more than $2.5 billion in debt and equity capital, including two IPOs and numerous follow-on equity offerings, private placements, convertible debt financings, and structured credit facilities. Pete joined CatalYm from Bluejay Therapeutics, where he served as CFO, and led financing initiatives and IPO readiness prior to its acquisition by Mirum Pharmaceuticals. Prior to Bluejay, he served as CFO of ALX Oncology Holdings Inc. where he led the Company’s IPO. Before that, he was CFO at PDL BioPharma, Inc., a profitable royalty management and specialty pharma holding company. He has also held CFO roles at other life science companies and began his biopharma career at Amgen Inc. in senior finance and controller roles. He holds an MBA in Finance and Accounting from the UCLA Anderson School of Management and a B.A. in Economics and Sociology with honors from Stanford University.